Idogen AB (publ) (IDOGEN)

Overview

Idogen AB (publ) stands out as a trailblazing biotechnology firm based in Lund, Sweden, with its roots going back to its incorporation in 2008. The company is at the forefront of developing tolerogenic cell therapies, which represent a groundbreaking approach in preventing the immune system's adverse reactions. These therapeutic advancements focus on stopping the immune system from attacking biological agents, transplanted organs, and even the body's own cells or tissues. This innovative direction highlights Idogen AB's commitment to resolving complex immune system challenges, particularly in contexts where the immune response can lead to critical complications, such as in transplanted organ rejection or autoimmune diseases.

Products and Services

• IDO 8

IDO 8 emerges as Idogen AB’s pioneering product candidate, specifically designed for patients suffering from severe haemophilia A. The condition is further complicated for those who have developed neutralizing antibodies against the crucial treatment with coagulation factor VIII. IDO 8 stands as a beacon of hope, aiming to provide an innovative solution that addresses and potentially overcomes the challenges posed by these neutralizing antibodies, thereby offering a new lease on life for patients affected by this severe form of haemophilia.

• IDO T

In the realm of organ transplantation, IDO T represents Idogen AB's ambitious venture to prevent organ transplant rejection, with a primary focus on kidney transplantation. This tolerogenic cell therapy is aimed at enhancing the long-term success rate of organ transplants by preventing the recipient’s immune system from rejecting the donated organ. The development of IDO T signifies a significant stride towards improving transplant outcomes and patient quality of life, underlining the company's dedication to addressing critical needs in organ transplantation.

• IDO AID

With the introduction of IDO AID, Idogen AB extends its expertise into the treatment of autoimmune diseases. This innovative therapy is under development to offer new therapeutic options for managing autoimmune conditions, where the body's immune system mistakenly attacks its own cells. IDO AID showcases the company's commitment to leveraging its tolerogenic cell therapy platform not only in organ transplantation and haemophilia but also in providing new avenues for treating autoimmune diseases, thus demonstrating its broad spectrum of potential therapeutic applications.